Sarcoma  >>  Imfinzi (durvalumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imfinzi (durvalumab) / AstraZeneca
NCT02423863: In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Completed
2
26
US
Hiltonol, Poly-ICLC, Nivolumab, Pembrolizumab, Atezolizumab, Cemiplimab, Durvalumab
Oncovir, Inc., National Institutes of Health (NIH), Icahn School of Medicine at Mount Sinai, Bay Hematology Oncology, National Cancer Institute (NCI), University of Missouri-Columbia, Chevy Chase Regional Cancer Care Associates LLC, Dermatologic Surgery Center of Washington LLC and Skin Cancer Treatment Center
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
08/20
08/20
NCT02879162: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Active, not recruiting
2
140
Canada
Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Advanced Rare Tumours
06/22
12/22
NCT03912818: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated
2
7
US
Carboplatin, Carboplat, Carboplatino, Carbosol, Paraplatin, Paraplatine, Cisplatin, Abiplatin, Briplatin, Cis-platinum, Cismaplat, Citoplatino, Plastistil, Platinol, Cystectomy, Doxorubicin, Adriablastin, Hydroxyl Daunorubicin, Rubex, Durvalumab, Imfinzi, MEDI-4736, Gemcitabine, Difluorodeoxycytidine, Gemzar, Methotrexate, Abitrexate, Amethopterin, Brimexate, Methotrexate Methylaminopterin, Metotrexato, Vinblastine, Vincaleucoblastine, Vinblastine Sulfate, vincaleukoblastine, sulfate
Stanford University, AstraZeneca
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
08/22
08/22
MEDISARC, NCT03317457 / 2016-004750-15: Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Completed
2
103
Europe
Durvalumab and Tremelimumab, Doxorubicin
AIO-Studien-gGmbH, AstraZeneca
Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
08/22
08/22
CAIRE, NCT04705818: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Completed
2
56
US
Durvalumab, Tremelimumab
M.D. Anderson Cancer Center, MedImmune LLC
Advanced and/or Metastatic Sarcoma
06/24
06/24
NCT02643303: A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Completed
1/2
58
US
Durvalumab, MEDI4736, Imfinzi®, Tremelimumab, Poly-ICLC, Hiltonol®
Ludwig Institute for Cancer Research, MedImmune LLC, Cancer Research Institute, New York City
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
02/22
02/22
NEXIS, NCT03116529: Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

Active, not recruiting
1/2
22
US
Combination Radiation, Immunotherapy, Surgery
University of Maryland, Baltimore, AstraZeneca, University of Arizona, West Penn Allegheny Health System
Soft Tissue Sarcoma
06/32
06/37

Download Options